Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
27-Jan-2026 | 270.05 | 270.2 | 259.5 | 268.35 | 13,706 | 5,98,76,848 | 1,04,976 |
28-Jan-2026 | 268 | 284.5 | 267.5 | 273.7 | 28,221 | 17,24,36,387.55 | 1,44,421 |
29-Jan-2026 | 275.85 | 275.9 | 268.35 | 269.95 | 9,529 | 4,50,36,231.6 | 81,285 |
30-Jan-2026 | 267.8 | 295 | 263.1 | 288.95 | 17,499 | 19,50,26,767.35 | 4,78,975 |
01-Feb-2026 | 294.75 | 325.3 | 275.5 | 288.1 | 1,28,632 | 1,66,67,70,577.6 | 3,62,044 |
02-Feb-2026 | 288 | 289.45 | 272 | 287.45 | 16,975 | 12,20,67,153.75 | 1,30,610 |
03-Feb-2026 | 310 | 310 | 294.75 | 299.95 | 20,021 | 14,09,50,372 | 2,34,928 |
04-Feb-2026 | 301 | 315.55 | 296.4 | 313.1 | 12,146 | 8,49,44,234.4 | 1,18,789 |
05-Feb-2026 | 311.5 | 318 | 308.8 | 315.9 | 8,391 | 5,38,07,107.15 | 82,401 |
06-Feb-2026 | 316.05 | 332 | 302.1 | 315.9 | 52,880 | 67,26,20,244.7 | 3,86,468 |
09-Feb-2026 | 329 | 350.9 | 325 | 332.6 | 62,402 | 89,27,27,543.75 | 6,66,067 |
10-Feb-2026 | 332.6 | 347 | 329.95 | 339.7 | 21,872 | 37,55,79,936.25 | 5,59,852 |
11-Feb-2026 | 339.8 | 339.8 | 330 | 331.5 | 7,901 | 7,76,41,018.45 | 93,328 |
12-Feb-2026 | 332 | 332.2 | 322.05 | 323.15 | 9,230 | 4,93,63,746.85 | 53,420 |
13-Feb-2026 | 320.8 | 336.25 | 316 | 326.8 | 18,671 | 15,25,00,100.7 | 1,65,153 |
16-Feb-2026 | 326.8 | 333.55 | 324.4 | 329.4 | 13,749 | 8,67,06,285.75 | 1,14,063 |
17-Feb-2026 | 329.4 | 334.45 | 324.9 | 333.6 | 8,338 | 4,26,74,485.7 | 60,097 |
18-Feb-2026 | 335 | 336.9 | 326.45 | 328.8 | 9,317 | 6,15,99,474.1 | 1,14,482 |
19-Feb-2026 | 328.8 | 334.4 | 326 | 328.8 | 7,743 | 7,16,82,735.9 | 1,33,926 |
20-Feb-2026 | 328.9 | 328.9 | 322.1 | 324.8 | 7,094 | 5,70,68,336.15 | 79,165 |
23-Feb-2026 | 324.85 | 329.05 | 317.3 | 326.75 | 12,245 | 6,79,62,108.85 | 1,00,719 |
24-Feb-2026 | 326.75 | 326.75 | 318.45 | 320.55 | 9,639 | 5,79,59,020.3 | 73,791 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
